Immix Biopharma (IMMX) Assets (2020 - 2026)
Immix Biopharma (IMMX) posted Assets of $95.8 million for Q1 2026, down 8.61% sequentially from $104.8 million in Q4 2025, and up 381.68% YoY from $19.9 million in Q1 2025.
Immix Biopharma (IMMX) Assets (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Assets for 7 years, with the latest figure at $95.8 million in Q1 2026.
- Quarterly Assets rose 381.68% year-over-year to $95.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.8 million (up 381.68% YoY) and the FY2025 annual result came in at $104.8 million, up 356.86% from the prior year.
- Assets retreated to $95.8 million in Q1 2026 per IMMX's latest filing, from $104.8 million in the prior quarter.
- Over five years, Assets peaked at $104.8 million in Q4 2025 and troughed at $13.2 million in Q1 2023.
- A 5-year average of $30.0 million and a median of $20.0 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2025 and 2026: Assets plunged 45.78% in 2025, then jumped 381.68% in 2026.
- Over 5 years, Assets stood at $14.9 million in 2022, then soared by 33.65% to $19.9 million in 2023, then grew by 15.17% to $22.9 million in 2024, then soared by 356.86% to $104.8 million in 2025, then dropped by 8.61% to $95.8 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $95.8 million, $104.8 million, and $20.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 239.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.11 Mn |
| Mar 31, 2026 | 95.82 Mn |
| Dec 31, 2025 | 104.84 Mn |
| Sep 30, 2025 | 20.08 Mn |
| Jun 30, 2025 | 15.64 Mn |
| Mar 31, 2025 | 19.89 Mn |
| Dec 31, 2024 | 22.95 Mn |
| Sep 30, 2024 | 25.14 Mn |
| Jun 30, 2024 | 28.84 Mn |
| Mar 31, 2024 | 34.35 Mn |
| Dec 31, 2023 | 19.93 Mn |
| Sep 30, 2023 | 22.47 Mn |
| Jun 30, 2023 | 15.57 Mn |
| Mar 31, 2023 | 13.21 Mn |
| Dec 31, 2022 | 14.91 Mn |
| Sep 30, 2022 | 17.40 Mn |
| Jun 30, 2022 | 19.09 Mn |
| Mar 31, 2022 | 20.02 Mn |
| Dec 31, 2021 | 18.19 Mn |
| Dec 31, 2020 | 539,597.00 |